Beyond potency, a good developability profile is a key attribute of a biological drug.
Selecting and screening for such attributes early in the drug development process can save …

There have been major advances in the immunotherapy of cancer in recent years, including
the development of T cell engagers—antibodies engineered to redirect T cells to recognize …

Bispecific T cell engagers (BiTEs), a subset of bispecific antibodies (bsAbs), can promote a
targeted cancer cell's death by bringing it close to a cytotoxic T cell. Checkpoint inhibitory T …

Despite the clinical success of the first bispecific antibody approved by the FDA against B
cell malignancies (blinatumomab), many obstacles remain such as dosing, treatment …

The efficacy and specificity of conventional monoclonal antibody (mAb) drugs in the clinic
require further improvement. Currently, the development and application of novel antibody …

In recent years there has been rising interest in the field of protein–protein conjugation,
especially related to bispecific antibodies (bsAbs) and their therapeutic applications. These …

Recombinant antibodies such as nanobodies are progressively demonstrating to be a valid
alternative to conventional monoclonal antibodies also for clinical applications. Furthermore …

Snakebite envenoming is a significant global health challenge, and for over a century,
traditional plasma-derived antivenoms from hyperimmunized animals have been the primary …

Despite advancements in cancer immunotherapy, heterogeneity in tumor response impose
barriers to successful treatments and accurate prognosis. Effective therapy and early …

Bispecific antibodies (bsAbs) are engineered molecules designed to target two different
epitopes or antigens. The mechanism of action is determined by the bsAb molecular targets …